ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ADMA
ADMA Biologics Inc (ADMA) EV/Sales
As of 16 October 2026, ADMA Biologics Inc (ADMA) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from 2.8× (January 2022) to 17.2× (April 2019); the current reading is higher than 25% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.5× | (8.84%) |
| FY2024 | 9.3× | 117.18% |
| FY2023 | 4.3× | (20.61%) |
| FY2022 | 5.4× | 76.26% |
| FY2021 | 3.1× | (38.21%) |
| FY2020 | 5.0× | (47.09%) |
| FY2019 | 9.4× | 25.77% |
| FY2018 | 7.5× | 133.63% |
| FY2017 | 3.2× | (40.85%) |
| FY2016 | 5.4× | (52.46%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.9× | (10.27%) |
| Mar 2026 | 4.3× | (49.47%) |
| Dec 2025 | 8.5× | 18.07% |
| Sep 2025 | 7.2× | (22.26%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MBX MBX Biosciences, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 1.8× |
| ADMA ADMA Biologics Inc | 4.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 5.6× |
| BEAM Beam Therapeutics Inc. compare | 8.9× |
| PGEN Precigen, Inc. compare | 27.2× |
| SLS SELLAS Life Sciences Group, Inc. compare | 167× |
| NAMS NewAmsterdam Pharma Company N.V. compare | 254× |
| CLDX Celldex Therapeutics, Inc. compare | 1,610× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)